Akebia Therapeutics, Inc.
AKBA
$0.88
$0.044.15%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -8.25% | -7.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -8.25% | -7.08% | |||
| Cost of Revenue | -2.07% | -10.54% | |||
| Gross Profit | -9.63% | -6.27% | |||
| SG&A Expenses | -7.44% | 16.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.84% | -13.58% | |||
| Operating Income | -81.15% | 75.53% | |||
| Income Before Tax | 1.01% | 20.53% | |||
| Income Tax Expenses | -44.44% | -87.51% | |||
| Earnings from Continuing Operations | 1.61% | 26.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.61% | 26.05% | |||
| EBIT | -81.15% | 75.53% | |||
| EBITDA | -81.94% | 79.88% | |||
| EPS Basic | 2.65% | 26.46% | |||
| Normalized Basic EPS | 10.45% | 34.95% | |||
| EPS Diluted | 2.65% | 31.93% | |||
| Normalized Diluted EPS | 10.45% | 34.95% | |||
| Average Basic Shares Outstanding | 0.96% | 0.63% | |||
| Average Diluted Shares Outstanding | 0.96% | 0.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||